Related Experiment Video
Updated: Nov 5, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.1K
Patient-Tailored Decision Support System Improves Short- and Long-Term Glycemic Control in Type 2 Diabetes
Petra Augstein1,2, Peter Heinke1, Lutz Vogt3
1Institute of Diabetes "Gerhardt Katsch", Karlsburg, Germany.
Journal of Diabetes Science and Technology
|May 18, 2021
Summary
A diabetes decision support system (DSS) improved glycemic control in type 2 diabetes (T2D) patients. The Q-Score effectively identified those needing intervention, optimizing therapy without increasing hypoglycemia.
Area of Science:
- Endocrinology
- Medical Informatics
- Diabetes Management
Background:
- Rising type 2 diabetes mellitus (T2D) prevalence and specialist shortages create a healthcare gap.
- Decision support systems (DSS) offer a potential solution to bridge this gap.
- Investigating the efficacy of a diabetes DSS in improving glycemic control is crucial.
Purpose of the Study:
- To evaluate the impact of a patient-tailored diabetes DSS on short- and long-term glycemic control in individuals with T2D.
- To assess the utility of the Q-Score in identifying patients with insufficient glycemic control.
- To determine if DSS intervention leads to improved glucose variability and HbA1c levels.
Main Methods:
- Retrospective observational cohort study of the Diabetiva program involving 452 T2D patients.
- Utilized a patient-tailored DSS (Karlsburger Diabetes-Management System - KADIS).
- Analyzed glycemic control using Time in Range (TIR), Q-Score, HbA1c, and glucose variability (GV) at baseline and 12 months.
Main Results:
- DSS application at baseline improved both short- and long-term glycemic control.
- A significant reduction in Q-Score, GV, and HbA1c was observed after 12 months.
- Multiple regression confirmed that all influential parameters contributed to the total effect on GV.
Conclusions:
- Diabetes DSS can effectively improve glycemic control in T2D patients without increasing hypoglycemia.
- The Q-Score is a valuable tool for identifying individuals with suboptimal glycemic control.
- Targeted DSS intervention for high-need T2D patients, identified by Q-Score, can optimize therapy.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
662
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
662
01:22Diabetes Mellitus: Type 2 and Gestational
3.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
01:16Insulin: Dosing Regimen and Adverse Effects
355
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
355
01:22Diabetes Mellitus: Overview and Type I Subtype
4.1K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.1K
01:36Carbohydrate Metabolism
12.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
12.8K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
389
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
389